Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023890 (
cirrhosis
)
42,195
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tyrosine (Tyr), tyrosine hydroxylase (TH), tryptophan (Trp), serotonin (5-HT), and 5-hydroxyindole acetic acid (5-HIAA) were assayed spectrofluorometrically and radioenzymatically in various regions of post-mortem brains of human patients with hepatic, uremic, and diabetic coma,
liver cirrhosis
without coma, and hepatic coma treated with parenteral administration of L-valine, a branched-chain amino acid. The results were as follows: In both hepatic and diabetic coma Tyr was increased as compared to non-comatose
cirrhosis
and controls, while TH acitivity was within normal limits, indicating sufficient oxygen supply of the brain in both types of coma. Brain DA showed a mild decrease in all types of metabolic coma. Brain Trp was not considerably changed in non-comatose cases of
liver cirrhosis
and after L-valine treatment of hepatic encephalopathy, but was significantly increased in hepatic coma, with highest elevation in the brainstem tegmentum. Both 5-HT and 5-HIAA were not significantly changed in non-comatose
cirrhosis
, while a general increase with prevalence for the brainstem was obvious in all types of metabolic coma. After L-valine treatment of hepatic coma, 5-HT levels were usually decreased below control values, while 5-HIAA levels were at or below controls. These results in human post-mortem brains confirm previous
CSF
and brain findings in experimental and human hepatic and uremic encephalopathies, indicating derangement of brain monoamine neurotransmitter metabolism which is attributed to imbalance of aromatic and branched-chain amino acids in plasma and brain. Increased cerebral 5-HT turnover, particularly in the ascending serotonergic brainstem systems, due to derangement of brain uptake of Trp is suggested to represent an important biochemical substrate of disorders of consciousness in hepatic failure and other types of metabolic encephalopathies. Clinical improvement of hepatic encephalopathy and of the underlying neurotransmitter derangements by administration of L-valine and the possible role of this competitive amino acid on intermediary metabolism and ammonia detoxification are discussed.
...
PMID:Brain monoamines in hepatic encephalopathy and other types of metabolic coma. 3 73
The concentrations of tryptophan in serum and
CSF
, as well as that of 5-HIAA in
CSF
were investigated in various group of patients. Those with
hepatic cirrhosis
have normal total serum tryptophan. However, because of the low concentration of serum albumin the percentage of nonalbumin-bound tryptophan is elevated about 50 percent above the mean control value. By contrast tryptophan in the
CSF
was increased by 50 to over 800 percent. This suggests that there is also an increase in brain tryptophan and serotonin in the cirrhotic patients. No significant difference was found for the concentrations of tryptophan in
CSF
of patients in coma and those not in coma. Patients with hepatic coma had an elevated concentration of 5-HIAA in the lumbar
CSF
which may reflect the increase in this compound and in serotonin reported by Jellinger and Riederer (1977). However, following treatment with probenecid in order to block the egress of 5-HIAA from the
CSF
, the concentration of 5-HIAA in relation to that of probenecid was not significantly different for the group with hepatic coma as compared with the control group.
...
PMID:Tryptophan in hepatic coma. 29 Jul 43
Tryptophan was measured in the lumbar
CSF
and serum of patients undergoing neurological investigation (controls) and in patients with
hepatic cirrhosis
. Samples were taken from the fasting patients at 8:00 a.m. Under these conditions, in the controls the mean
CSF
, free )mpm-albumin-bound) and total serum tryptophan were in the approximate ratio 1:4:24. In this cross-sectional study, for the controls,
CSF
tryptophan was correlated significantly and positively with the total serum but not with the free serum tryptophan. In patients with advanced
hepatic cirrhosis
the mean
CSF
tryptophan concentration was greatly elevated. However, the mean total serum tryptophan was unchanged and the free serum tryptophan only slightly elevated. Administration of probenecid, which displaces tryptophan from binding sites on serum albumin, and thereby increases the proportion of serum tryptophan in the free form, did not affect
CSF
tryptophan.
...
PMID:Relationships between tryptophan in serum and CSF, and 5-hydroxyindoleacetic acid in CSF of man: effect of cirrhosis of liver and probenecid administration. 114 19
CSF
from neurological and other patients was analyzed for its content of tryptophan, 5-HIAA and homovanilic acid (HVA). The gradients of concentration of these substances from ventricular spaces to lumbar sac indicate that tryptophan and 5-HIAA probably enter the
CSF
from all levels of the nervous system, but that HVA originates entirely in the brain. A study of
CSF
tryptophan in patients with
hepatic cirrhosis
provided no support for theories which implicate abnormal tryptophan metabolism as a cause of hepatic coma.
...
PMID:Gradients of concentrations of tryptophan and 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF). 124 32
A 63-year-old Japanese woman who was being treated for
liver cirrhosis
was diagnosed as having hepatocellular carcinoma in the caudate lobe of the liver. Transcatheter hepatic arterial chemoembolization was performed for this lesion, but severe neutropenia occurred. To restore white blood cell (WBC) counts, recombinant human granulocyte colony-stimulating factor (rhG-CSF) was administered (250 micrograms per day during 10 days, intravenously). Subsequently, WBC counts recovered immediately without side effects. This suggests that rhG-
CSF
could be useful for the treatment of neutropenia after chemoembolization, even in cirrhotic patients.
...
PMID:An application of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in a case of hepatocellular carcinoma combined with liver cirrhosis in which leukopenia developed after chemoembolization. 172 72
Central nervous system (CNS)-induced natriuresis was investigated in nonascitic rats with CCl4-induced
cirrhosis
(CTC rats) under pentobarbital anesthesia. At baseline, urine sodium output (UNa+V, in mumol.min-1.100 g body wt-1) (-30%, P less than 0.01) and mean arterial pressure (MAP, in mmHg) (-12%, P less than 0.001) were significantly reduced in CTC rats (n = 32) compared with matched controls (n = 34). In response to intracerebroventricular infusion of sodium-rich (349 mM) artificial cerebrospinal fluid (Na(+)-
CSF
infusion), UNa+V was significantly higher in CTC rats (2.8 +/- 0.3; n = 15) than in controls (1.7 +/- 0.2; n = 17; P less than 0.01); no differences were found in pressor changes (24 +/- 3 vs. 19 +/- 2). A similar but normal sodium
CSF
(150 mM) infusion did not influence UNa+V or MAP in any group (n = 12, both). In contrast, CTC rats (n = 5) showed, compared with controls (n = 5), significantly reduced natriuretic (UNa+V, 6.9 +/- 0.5 vs. 12.4 +/- 0.9; P less than 0.001) and pressor (+16 +/- 3 vs. +31 +/- 2; P less than 0.01) responses to an intravenous hypertonic sodium overload. Natriuresis induced by Na(+)-
CSF
infusion was related to increases in creatinine clearance (similar in both groups) and in fractional sodium excretion, which was significantly higher in CTC rats (5.90 +/- 0.15%) than in controls (3.65 +/- 0.14%; P less than 0.01). In summary, CNS-dependent efferent natriuretic mechanisms were preserved in CTC rats and were able to reverse renal tubular sodium retention in these animals. It is proposed that Na(+)-
CSF
infusion may be a useful tool for the study of renal sodium retention in experimental
liver cirrhosis
.
...
PMID:Enhanced responsiveness to CNS-induced natriuresis in anesthetized nonascitic cirrhotic rats. 205 81
Significant elevation of glutamic acid and glutamine concentrations in
CSF
was observed in hepatic encephalopathic patients with fulminant hepatitis and
liver cirrhosis
. However, the ratios of
CSF
glutamic acid to
CSF
glutamine levels and of
CSF
to serum glutamic acid and glutamine levels were significantly higher only in cirrhotic patients with hepatic encephalopathy.
CSF
glutamine levels were positively correlated with blood ammonia and
CSF
tyrosine levels in cirrhotic patients. The results indicate that
CSF
glutamic acid and glutamine levels are important tools in diagnosing hepatic encephalopathy in severe liver disease.
...
PMID:Glutamic acid and glutamine levels in serum and cerebrospinal fluid in hepatic encephalopathy. 615 Jul 6
Hepatic encephalopathy in patients with severe liver disease was associated with marked elevation of either serum methionine or blood ammonia levels or with simultaneous moderate increases in both parameters.
CSF
methionine levels also increased in encephalopathic patients with fulminant hepatitis and
liver cirrhosis
. Increased influx of methionine into the brain over the theoretical values predicted from Pardridge's equation suggested that accelerated transport of serum methionine across the blood-brain barrier was observed in these cases with hepatic encephalopathy. Hepatic encephalopathy in acute carbon tetrachloride liver injury could be obtained experimentally following intraperitoneal injection of ammonium acetate in rats, which already received intragastric administration of methionine. However, similar encephalopathy could not be observed by the administration of glycine or leucine in place of methionine. These results suggest at least that methionine and ammonia act synergistically on inducing hepatic encephalopathy.
...
PMID:Impaired metabolism of methionine in severe liver diseases. II. Clinical and experimental studies on role of impaired methionine metabolism in pathogenesis of hepatic encephalopathy. 710 99
Lumbar
CSF
indoleacetic acid (IAA) was higher in patients with
cirrhosis of the liver
than in controls. It was also higher in
CSF
of patients in coma than in those with
hepatic cirrhosis
but not in coma. There was a strong correlation (r = 0.89, p less than 0.01) between the grade of hepatic coma and
CSF
IAA. These data indicate that there is an association between elevated CNS tryptamine metabolism and hepatic coma. How far changes in the metabolism of tryptamine and other trace amines are relevant to the induction of hepatic coma or are simply a reflection of advanced liver dysfunction is unclear.
...
PMID:CNS tryptamine metabolism in hepatic coma. 738 53
Interferon therapy in cirrhotic patients with hepatitis C virus infection is not efficient. In an attempt to improve the response rate, a pilot study using recombinant human granulocyte colony-stimulating factor (rhG-CSF) alone, and in combination with recombinant interferon-alpha (rIFN), was carried out. Fifteen cirrhotic patients with hepatitis C virus infection were randomly allocated into 3 groups to receive treatment: 0.5, 1, or 1.5 micrograms/kg of rhG-
CSF
daily for 4 weeks, followed by a 4 week resting period, and by the same dose of rhG-
CSF
daily, plus 6 MU of rIFN 3 times weekly for 4 weeks. They then continued to receive 6 MU of rIFN alone for 4 weeks, followed by 3 MU of rIFN for 16 weeks. After the 4 weeks of treatment with rhG-
CSF
alone, no changes in alanine aminotransferase (ALT) levels were observed. No changes occurred during the resting period. Three of 10 patients who ended the rhG-
CSF
plus rIFN treatment period had normal ALT values. During the treatment with rIFN alone, two responders suffered a relapse. The other responder had normal ALT until the first month of follow-up. In summary, the combination of rhG-
CSF
and rIFN seems promising for the treatment of patients with chronic hepatitis C and
liver cirrhosis
.
...
PMID:Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha. 754 14
1
2
3
Next >>